Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962184 | 0.83 | SLC6A4 (0.52) | PRMT5WDR77GBA1SLC6A4SLC6A2 | |
| SCHEMBL5207446 | 0.81 | SLC6A4 (0.48) | GBA1SLC6A4 | |
| SCHEMBL6858425 | 0.81 | SLC6A4 (0.58) | PRMT5WDR77GBA1SLC6A4SLC6A2 | |
| SCHEMBL5215765 | 0.77 | SLC6A4 (0.48) | GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6851296 | 0.77 | SLC6A4 (0.56) | SLC6A4SLC6A2 | |
| SCHEMBL23230320 | 0.77 | PRMT5 (0.44) | PRMT5WDR77GBA1SLC6A4P2RX7 | |
| SCHEMBL3161884 | 0.76 | GBA1 (0.56) | GBA1SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL5205056 | 0.76 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6855547 | 0.75 | SLC6A4 (0.43) | PRMT5WDR77SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL18280044 | 0.75 | GBA1 (0.55) | GBA1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | claimed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | claimed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | claimed |
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | PRMT5 538/4885WDR77 2463/4885GBA1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.